房颤患者从维生素K拮抗剂切换到达比加群:剂量差异:回复。

{"title":"房颤患者从维生素K拮抗剂切换到达比加群:剂量差异:回复。","authors":"Naja Emborg Vinding, Lars Køber, Emil Loldrup Fosbøl","doi":"10.1093/ehjcvp/pvaa023","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"75"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa023","citationCount":"0","resultStr":"{\"title\":\"Comment on-Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply.\",\"authors\":\"Naja Emborg Vinding, Lars Køber, Emil Loldrup Fosbøl\",\"doi\":\"10.1093/ehjcvp/pvaa023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11995,\"journal\":{\"name\":\"European Heart Journal — Cardiovascular Pharmacotherapy\",\"volume\":\" \",\"pages\":\"75\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa023\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal — Cardiovascular Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjcvp/pvaa023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal — Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvaa023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}